Aclaris Therapeutics ACRS
- ATI-2138 — Atopic Dermatitis Phase 2
- lepzacitinib — Atopic Dermatitis Phase 2
- modzatinib — Lichen Planus Phase 2
JAK3 (1 companies · 3 programs)
Companies with an active program directed at JAK3.
Companies with an active program directed at JAK3.